| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 435700950 | Indirect assay | 12 |
| 20120040382 | METHOD OF DETECTING PROGRESSION OF A NEURODEMENTING DISEASE - Isolated, monoclonal, human, anti-β-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an Aβ polypeptide comprising Aβ(21-37) shield Aβ(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided. | 02-16-2012 |
| 20120107848 | POLYCLONAL-MONOCLONAL ELISA ASSAY FOR DETECTING N-TERMINUS PRO-BNP - A specific and sensitive in vitro ELISA assay and diagnostic test kit is disclosed for determining levels of NT-proBNP protein in a variety of bodily fluids, non-limiting examples of which are blood, serum, plasma, urine and the like. The NT-proBNP ELISA assay test employs the sandwich ELISA technique to measure circulating NT-proBNP in human plasma. In order to obtain antibodies with specific binding properties for targeted amino acid sequences within human proBNP, recombinant human proBNP (or rhproBNP) was expressed and purified for use as an immunogen. Polyclonal antibodies (PAb) to specific amino acid sequences were subsequently purified from goat serum by sequential affinity purification. Monoclonal antibodies were raised against specific polypeptides. Recombinant human NT-proBNP (or rhNT-proBNP) was expressed and purified in order to obtain material for use in calibration of a quantitative method for measurement of human NT-proBNP. | 05-03-2012 |
| 20120129200 | PRODEFENSIN-A6 ASSAY METHOD FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER - The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Prodefensin-A6 tumour marker in a biological sample taken from a patient suspected of having colorectal cancer, it being possible for said method to be used both in early diagnosis, screening, therapeutic follow-up and prognosis, and in relapse diagnosis in relation to colorectal cancer. | 05-24-2012 |
| 20120178113 | DETECTION OF IGFBP-4 FRAGMENTS AS A DIAGNOSTIC METHOD - The present invention relates to a method for diagnosing a cardiovascular or cancer disease by detecting IGFBP-4 (Insulin-like Growth Factor Binding Protein-4) fragments in a patient sample. Antibodies specifically recognizing novel epitopes originated by enzyme-dependent cleavage of IGFBP-4 are also disclosed. | 07-12-2012 |
| 20120214187 | Method for Enhancing the Sensitivity of Antibody Based Assays - There is a constant need for increased sensitivity of antibody-based assays as well as a need for high affinity antibodies. Higher affinity molecules such as antibodies increase the specificity and sensitivity of assays. Both increased sensitivity and higher affinity can be achieved when multiple copies of a binding molecule are coupled to a flexible backbone. According to one embodiment of the invention, multiple copies of a detection molecule, such as, for example, an antibody or antibody fragment, are covalently linked to a high molecular weight water soluble polymer creates multivalent antibody constructs. The affinity or avidity increases markedly as multivalency increases and also, multiple copies of a signal molecule can be similarly added to the polymer. Thus, the construct comprises multiple copies of detection and signal molecules on a high molecular weight, water soluble, flexible polymer. Broadly, the invention comprises a multiplicity of detection molecules (D) and a multiplicity of signal molecules (S) on a polymer (P), such that P | 08-23-2012 |
| 20130109036 | PROTEIN SUBSTRATE AND ITS MANUFACTURING METHOD | 05-02-2013 |
| 20140017714 | METHOD FOR DETERMINING THE RISK OF CARDIOVASCULAR EVENTS USING IGFBP FRAGMENTS - The present invention describes the method for determining the risk of future major adverse cardiovascular events, which comprises detection proteolytic fragments of IGFBP-4 or IGFBP-5 (insulin-like growth factor binding protein 4 or insulin-like growth factor binding protein 5) in patients' blood. The present invention provides antibodies and immunoas-says, suitable for specific measurement of proteolytic fragments of IGFBPs. In current invention the IGFBP fragments are suggested to be utilized as blood biomarkers for the risk prediction of major adverse cardiovascular events (MACE). | 01-16-2014 |
| 20140349324 | SOLUBLE ST2 AS A MARKER FOR RISK OF MORTALITY IN HIV-INFECTED SUBJECTS - The present invention relates to materials and methods concerning the IL-1 receptor family protein ST2. Use of soluble ST2 as a marker for cardiovascular disease or disease outcome is provided, in particular as a marker of the risk of mortality. | 11-27-2014 |
| 20150093769 | METHOD FOR DETERMINING THE CONCENTRATION OF THE ADIPOCYTIC FORM OF THE FATTY ACID BINDING PROTEIN (A-FABP, FABP4, P2) - Products and methods for the research, diagnosis, risk assessment, course monitoring, treatment and prophylaxis of various metabolic disorders and their early forms, concomitant diseases and secondary diseases are provided. Metabolic diseases include, for example, metabolic syndrome, non-insulin-dependent diabetes, (type II diabetes), insulin resistance, obesity (adiposis), in addition to diseases that are associated with disorders of the fatty acid metabolism. Methods may include analysis of the concentration of the adipocytic form of the fatty acid binding protein (A-FABP, FABP 4, P2) in various bodily fluids. | 04-02-2015 |
| 20150346220 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR ALZHEIMER'S DISEASE - The inversion relates to diagnosing the presence or absence of antibodies, such as IgM, IgG or IgA antibodies, related to increased or decreased risk of developing Alzheimer's disease, using a phosphorylcholine conjugate. In addition, the invention relates to methods of immunization and prophylaxis, prevention and/or treatment of a subject against Alzheimer's disease, the method comprising the step of administering to the subject a pharmaceutical composition comprising at least one phosphorylcholine conjugate, or the step of administering to the subject an antibody preparation, for example a monoclonal antibody, with reactivity to a phosphorylcholine and/or a conjugate thereof. | 12-03-2015 |
| 20150377902 | Serological Methods and Diagnostic Tests for Syphilis Antibodies - A method of detecting antibodies to syphilis antigens includes providing a syphilis detection kit having a screening solid-phase platform with a screening portion coated with non-treponemal syphilis antigens. The screening portion is fabricated by initially dissolving cholesterol in an organic solvent and further diluting the dissolved cholesterol in an ethanol solution comprising cardiolipin and lecithin to form an antigen solution, permitting the antigen solution to evaporate at the screening portion and at least partially coating the screening portion with an antigen coating, and stabilizing the antigen coating into a syphilis antigen complex by overcoating the antigen coating with an overcoat solution comprising an inert protein. | 12-31-2015 |
| 20160076002 | Bioassay for Cell Conditioned Media - Herein is described a novel hybridoma cell line (RMH359) and its use as a cellular bioassay to determine the efficacy of cell conditioned media (CCM) as a supplement used to support cell survival and promote growth in culture. This bioassay is the first to provide a measure of CCM bioactivity in support of hybridoma cells used in the generation and production of monoclonal antibodies. | 03-17-2016 |
